A securities class action has been filed against Medpace Holdings, Inc., (MEDP) on behalf of all investors who purchased or otherwise acquired Medpace common stock between April 22, 2025 through February 9, 2026. This case has been filed in the USDC – SDOH.
Medpace is a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The Company’s operating model centers on providing full-service Phase I-IV clinical development services and therapeutic expertise.
Medpace’s stock price fell $79.88, or 18.3%, to close at $357.30 per share on July 23, 2024, thereby injuring investors. This sharp decline followed the July 22, 2024, post-market release of the Company’s second quarter 2024 financial results, which significantly underperformed relative to expectations. During a subsequent earnings call on July 23, management revealed that “cancellations were disproportionately high in the month of June.” The Company identified several drivers for this trend, including “impaired sponsor liquidity,” “reprioritization,” and a specific instance where a sponsor was acquired by a large pharmaceutical firm that opted to “move the work to an existing preferred provider,” effectively terminating the Medpace contract.
The complaint alleges that Defendants made materially false and misleading statements and engaged in a scheme to deceive the market and a course of conduct that artificially inflated the price of Medpace’s common stock and operated as a fraud or deceit on Class Period purchasers of Medpace’s common stock by materially misleading the investing public. Later, Defendants’ prior misrepresentations and fraudulent conduct became apparent to the market, the price of Medpace’s common stock materially declined, as the prior artificial inflation came out of the price over time. As a result of their purchases of Medpace’s common stock during the Class Period, Plaintiff and other members of the Class suffered economic loss, i.e., damages under federal securities laws.